![](https://myastheniagravis.org/wp-content/uploads/2022/09/assessment-online-survey-6078645_1280-300x100.png)
In January 2022, an Illinois-based specialty pharmaceutical company collaborated on a project with Conquer MG to gain insights from MG patients. Conquer MG helped with study review and recruitment, and a study of 102 MG patients was conducted that addressed their use of pyridostigmine (brand name Mestinon®). Pyridostigmine is typically the first drug MG patients… Read more »